| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, University of Munich, Germany.
Address correspondence and reprint requests to Prof. M. Strupp, Department of Neurology, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany; e-mail: mstrupp{at}nefo.med.uni-muenchen.de
Background: Several drugs that primarily act on 
-aminobutyrate or muscarinic receptors have been used to treat downbeat nystagmus (DBN) syndrome despite their having only moderate success and causing several side effects that limit their effectiveness. These drugs were tested under the assumption that DBN was caused by a disinhibition of a physiologic inhibitory cerebellar input on vestibular nuclei.
Objective: To evaluate the effects of a single dose of the potassium channel blocker 3,4-diaminopyridine (3,4-DAP), which is known to increase the excitability of Purkinje cells, on DBN in a prospective, placebo-controlled, double-blind study with a crossover design.
Methods: Seventeen patients with DBN due to cerebellar atrophy (5), infarction (3), Arnold–Chiari malformation (1), or unknown etiology (8) were included in the study (1 of 18 patients had to be excluded). Mean peak slow-phase velocity (PSPV) was measured before and 30 minutes after randomized ingestion of 20 mg of 3,4-DAP or placebo orally; at least 1 week later, the treatments were switched.
Results: 3,4-DAP reduced mean PSPV of DBN from 7.2 ± 4.2°/s (mean ± SD) before treatment to 3.1 ± 2.5°/s 30 minutes after ingestion of the 3,4-DAP (p < 0.001, two-way analysis of variance). Placebo had no measurable effect. In 10 of 17 subjects, the mean PSPV decreased by >50% and in 12 of 17 by >40%. In parallel, the subjects had less oscillopsia and felt more stable while standing and walking. Nine of the subjects continued to take the drug with success. Except for transient minor perioral or digital paresthesia reported by three subjects and nausea and headache reported by one, no other side effects were observed.
Conclusions: In this study, the authors demonstrated that a single dose of 3,4-DAP significantly improved DBN. In view of animal studies reporting that micromolar concentrations of 4-aminopyridine increased the excitability of Purkinje cells, it is suggested that the efficacy of 3,4-DAP may be due to an increase of the physiologic inhibitory influence of the vestibulocerebellum on the vestibular nuclei.
This article has been cited by other articles:
|
|
 |
|
  J N Wagner, M Glaser, T Brandt, and M Strupp Downbeat nystagmus: aetiology and comorbidity in 117 patients J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 672 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.C. Jen, T.D. Graves, E.J. Hess, M.G. Hanna, R.C. Griggs, R.W. Baloh, and the CINCH investigators Primary episodic ataxias: diagnosis, pathogenesis and treatment Brain, October 1, 2007; 130(10): 2484 - 2493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hufner, T. Stephan, R. Kalla, A. Deutschlander, J. Wagner, M. Holtmannspotter, G. Schulte-Altedorneburg, M. Strupp, T. Brandt, and S. Glasauer Structural and functional MRIs disclose cerebellar pathologies in idiopathic downbeat nystagmus Neurology, September 11, 2007; 69(11): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kalla, S. Glasauer, U. Buttner, T. Brandt, and M. Strupp 4-Aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus Brain, September 1, 2007; 130(9): 2441 - 2451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Martina, A. E. Metz, and B. P. Bean Voltage-Dependent Potassium Currents During Fast Spikes of Rat Cerebellar Purkinje Neurons: Inhibition by BDS-I Toxin J Neurophysiol, January 1, 2007; 97(1): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sprenger, H. Rambold, T. Sander, S. Marti, K. Weber, D. Straumann, and C. Helmchen Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine. Neurology, September 12, 2006; 67(5): 905 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Shery, F A Proudlock, N Sarvananthan, R J McLean, and I Gottlob The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study Br. J. Ophthalmol., July 1, 2006; 90(7): 839 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lorenz, K. Hagen, M. Ufer, I. Cascorbi, G. Deuschl, and J. Volkmann No benefit of 3,4-diaminopyridine in essential tremor: A placebo-controlled crossover study Neurology, June 13, 2006; 66(11): 1753 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. C. Weisz, R. S. Raike, L. E. Soria-Jasso, and E. J. Hess Potassium Channel Blockers Inhibit the Triggers of Attacks in the Calcium Channel Mouse Mutant tottering J. Neurosci., April 20, 2005; 25(16): 4141 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SPRENGER, E. ZILS, H. RAMBOLD, T. SANDER, and C. HELMCHEN Effect of 3,4-Diaminopyridine on the Postural Control in Patients with Downbeat Nystagmus Ann. N.Y. Acad. Sci., April 1, 2005; 1039(1): 395 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. GLASAUER, M. STRUPP, R. KALLA, U. BUTTNER, and T. BRANDT Effect of 4-Aminopyridine on Upbeat and Downbeat Nystagmus Elucidates the Mechanism of Downbeat Nystagmus Ann. N.Y. Acad. Sci., April 1, 2005; 1039(1): 528 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Glasauer, R Kalla, U Buttner, M Strupp, and T Brandt 4-aminopyridine restores visual ocular motor function in upbeat nystagmus J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 451 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Danchaivijitr and C Kennard Diplopia and eye movement disorders J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(suppl_4): iv24 - iv31. [Full Text] [PDF]
|
|
|
|
|
|
S. Glasauer, H. von Lindeiner, C. Siebold, and U. Buttner Vertical vestibular responses to head impulses are symmetric in downbeat nystagmus Neurology, August 24, 2004; 63(4): 621 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Helmchen, A. Sprenger, H. Rambold, T. Sander, D. Kompf, and D. Straumann Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus Neurology, August 24, 2004; 63(4): 752 - 753. [Full Text] [PDF]
|
|
|
|
|
|
M. Strupp, R. Kalla, M. Dichgans, T. Freilinger, S. Glasauer, and T. Brandt Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine Neurology, May 11, 2004; 62(9): 1623 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kalla, S. Glasauer, F. Schautzer, N. Lehnen, U. Buttner, M. Strupp, and T. Brandt 4-Aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain Neurology, April 13, 2004; 62(7): 1228 - 1229. [Full Text] [PDF]
|
|
|
|
|
|
C. B. PEREIRA, M. STRUPP, V. C. ZINGLER, and T. BRANDT Two Opposite Effects of Nicotine on Downbeat Nystagmus: An Observation Ann. N.Y. Acad. Sci., October 1, 2003; 1004(1): 492 - 496. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Leigh Potassium channels, the cerebellum, and treatment for downbeat nystagmus Neurology, July 22, 2003; 61(2): 158 - 159. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
